Anders Ullén

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Adjungerad professor i klinisk onkologi vid institutionen för
onkologi-patologi från 1 juli 2021. Primär anställning: Överläkare vid
enheten bäckencancer, Tema cancer vid Karolinska Universitetssjukhuset. För
mer information, se den engelska profilsidan.

Artiklar

Article: BJU INTERNATIONAL. 2024;134(2):229-238
Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations
Holmberg L; Skogmar S; Garmo H; Hagberg O; Haggstrom C; Gardmark T; Strock V; Aljabery F; Jahnson S; Hosseini A; Jerlstrom T; Sherif A; Soderkvist K; Ullen A; Malmstrom P-U; Liedberg F
Article: EUROPEAN UROLOGY. 2024;85(2):154-163
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Sridhar SS; Powles T; Duran MAC; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullen A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2024;59:19-25
Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey
Liedberg F; Hagberg O; Aljabery F; Gardmark T; Jahnson S; Jerlstrom T; Strock V; Soderkvist K; Ullen A; Bobjer J
Article: INTERNATIONAL JOURNAL OF CANCER. 2024;154(1):180-190
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer
Sjodahl G; Eriksson P; Holmsten K; Abrahamsson J; Hoglund M; Bernardo C; Ullen A; Liedberg F
Article: CLINICAL GENITOURINARY CANCER. 2023;21(6):e438-e448
Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
Holmsten K; Eknert J; Ofverholm E; Papantoniou D; Jawdat F; Verbiene I; Laurell A; Janes E; Sandzen J; Wojtyna-Dziedzic E; Lagstam I; Soderkvist K; Svedman FC; Liedberg F; Bruzelius M; Fransson A-S; Kjellstrom S; Omland LH; Pappot H; Ullen A
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2023;57(1-6):15-21
Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019
Karttunen E; Hervonen P; Hosseini Aliabad A; Oldenburg J; Pappot H; Sairanen J; Stovring H; Vasquez JL; Bergman S; Magnussen G; Norremark P; Thoresen S; Ullen A
Article: EUROPEAN UROLOGY. 2023;84(1):95-108
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullen A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(19):3486-3492
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up
Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullen A; Loriot Y; Sridhar SSS; Sternberg CNN; Bellmunt J; Aragon-Ching JBB; Wang J; Huang B; Laliberte RJJ; di Pietro A; Grivas P
Article: PROSTATE. 2023;83(10):950-961
Transcriptomic analysis of plasma exosomes provides molecular information of response to cabazitaxel treatment in men with metastatic castration-resistant prostate cancer
Vardaki I; Ozcan SS; Fonseca P; Lin S-H; Logothetis CJ; Yachnin J; Ullen A; Panaretakis T
Article: EJSO. 2023;49(4):868-874
Short term outcomes after robot assisted and open cystectomy- A nation-wide population-based study
Bergengren O; Belozerov A; Bill-Axelson A; Garmo H; Hagberg O; Aljabery F; Gardmark T; Jahnson S; Jerlstrom T; Malmstrom P-U; Sherif A; Strock V; Souroderkvist K; Ullen A; Holmberg L; Haggstrom C; Liedberg F
Article: EUROPEAN JOURNAL OF CANCER. 2023;181:198-207
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases
Thellenberg-Karlsson C; Vjaters E; Kase M; Tammela T; Ojamaa K; Norming U; Nyman C; Andersson S-O; Hublarovs O; Marquez-Holmberg M; Castellanos E; Ullen A; Holmberg A; Nilsson S
Article: CLINICAL GENITOURINARY CANCER. 2023;21(1):107.e1-107.e9
Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden
Stattin P; Westerberg M; Lissbrant IF; Eriksson MH; Kjellman A; Ullen A; Vassilev Z; Sandstrom P; Weinrib R; Martinez D; Garcia-Albeniz X
Article: PLOS ONE. 2023;18(2):e0281304
Preoperative upper tract invasive diagnostic modalities are associated with intravesical recurrence following surgery for upper tract urothelial carcinoma: A population-based study
Liedberg F; Hagberg O; Haggstrom C; Aljabery F; Gardmark T; Hosseini A; Jahnson S; Jerlström T; Ströck V; Söderkvist K; Ullen A; Holmberg L; Bobjer J
Article: BMJ OPEN. 2022;12(12):e064898
Cohort profile: Bladder Cancer Data Base Sweden (BladderBaSe) 2.0
Haggstrom C; Hagberg O; Gardmark T; Aljabery F; Stroeck V; Hosseini A; Sherif A; Malmstrom P-U; Soderkvist K; Ullen A; Jerlstrom T; Jahnson S; Liedberg F; Holmberg L
Article: ACTA ONCOLOGICA. 2022;61(10):1179-1185
High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation
Hjalm-Eriksson M; Ullen A; Nilsson S; Johansson H; Nilsson J; Castellanos E; Brandberg Y
Article: MOLECULAR ONCOLOGY. 2022;16(20):3620-3641
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome
Viktorsson K; Haag P; Shah C-H; Franzen B; Arapi V; Holmsten K; Sandstrom P; Lewensohn R; Ullen A
Article: FUTURE ONCOLOGY. 2022;18(19):2361-2371
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullen A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte RJ; Huang B; Costa N; Blake-Haskins JA; Grivas P
Article: EUROPEAN UROLOGY. 2022;81(5):523-532
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lovgren K; Marzouka N-A; Olsson H; Hoglund M; Ullen A; Liedberg F
Article: BLADDER CANCER. 2022;8(1):71-80
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen
Holmsten K; Omland LH; Als AB; Agerbaek M; Dohn LH; Lindberg H; Jensen NV; Carus A; Moe M; Hosseini A; Radkiewicz C; Pappot H; Ullen A
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2022;56(2):137-146
Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
Liedberg F; Kjellstrom S; Lind A-K; Sherif A; Soderkvist K; Falkman K; Thulin H; Aljabery F; Papantonio D; Strock V; Ofverholm E; Jerlstrom T; Sandzen J; Verbiene I; Ullen A
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2022;56(1):27-33
Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer
Russell B; Liedberg F; Hagberg O; Ullen A; Soderkvist K; Strock V; Aljabery F; Gardmark T; Jerlstrom T; Sherif A; Holmberg L; Bryan RT; Enting D; Van Hemelrijck M
Article: PLOS ONE. 2022;17(9):e0274859
Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer
Holmberg L; Hagberg O; Haggstrom C; Gardmark T; Strock V; Aljabery F; Jahnson S; Hosseini A; Jerlstrom T; Sherif A; Soderkvist K; Ullen A; Enlund M; Liedberg F; Malmstrom P-U
Article: ACTA ONCOLOGICA. 2021;60(10):1301-1307
High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience
Hjalm-Eriksson M; Nilsson S; Brandberg Y; Johansson H; Lennernas B; Lundell G; Castellanos E; Ullen A
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2021;55(5):361-365
Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort
Magnusson J; Hagberg O; Aljabery F; Hosseini A; Jahnson S; Jerlstrom T; Sherif A; Soderkvist K; Strock V; Ullen A; Haggstrom C; Holmberg L; Kjolhede H
Article: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2021;48(10):3325-3334
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
van der Doelen MJ; Stockhaus A; Ma Y; Mehra N; Yachnin J; Gerritsen WR; Nilsson S; van Oort IM; Ullen A
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2021;55(4):276-280
Survival after radical cystectomy during holiday periods
Liedberg F; Hagberg O; Aljabery F; Gardmark T; Hosseini A; Jahnson S; Jerlstrom T; Malmstrom P-U; Sherif A; Soderkvist K; Strock V; Ullen A; Haggstrom C; Holmberg L
Article: BLADDER CANCER. 2021;7(2):161-171
Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study
Jahnson S; Gardmark T; Hosseini A; Jerlstrom T; Liedberg F; Malmstrom P-U; Hagberg O; Sherif A; Strock V; Soderkvist K; Ullen A; Haggstrom C; Holmberg L; Aljabery F
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;383(13):1218-1230
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullen A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte R; Wang J; Huang B; Davis C; Fowst C; Costa N; Blake-Haskins JA; di Pietro A; Grivas P
Article: TRIALS. 2020;21(1):579
The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
Crippa A; De Laere B; Discacciati A; Larsson B; Connor JT; Gabriel EE; Thellenberg C; Janes E; Enblad G; Ullen A; Hjalm-Eriksson M; Oldenburg J; Ost P; Lindberg J; Eklund M; Gronberg H
Article: JOURNAL OF NUCLEAR MEDICINE. 2020;61(5):671-675
Assessing Radiographic Response to ²²³Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients
Anand A; Tragardh E; Edenbrandt L; Beckman L; Svensson J-H; Thellenberg C; Widmark A; Kindblom J; Ullen A; Bjartell A
Article: EUROPEAN JOURNAL OF CANCER. 2020;127:173-182
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)
Holmsten K; Jensen NV; Mouritsen LS; Jonsson E; Mellnert C; Agerbaek M; Nilsson C; Moe M; Carus A; Ofverholm E; Lahdenpera O; Brandberg Y; Johansson H; Hellstrom M; von der Maase H; Pappot H; Ullen A
Article: WORLD JOURNAL OF UROLOGY. 2020;38(2):381-388
No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study
Jerlstrom T; Chen R; Liedberg F; Andren O; Strock V; Aljabery FAS; Hosseini A; Sherif A; Malmstrom P-U; Ullen A; Gardmark T; Fall K
Article: ONCOLOGIST. 2019;24(6):745-e213
Safety and Activity of Sorafenib in Addition to Vinflunine in Post-Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
Shah C-H; Pappot H; Agerbaek M; Holmsten K; Jaderling F; Yachnin J; Gryback P; von der Maase H; Ullen A
Article: CLINICAL CANCER RESEARCH. 2019;25(6):1766-1773
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer
De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam P-J; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullen A; Yachnin J; Gronberg H; Van Laere SJ; Lindberg J; Dirix LY
Article: GENOME MEDICINE. 2018;10(1):85
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam P-J; Van den Eynden G; Rutten A; Aly M; Nordstrom T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullen A; Yachnin J; Dirix L; Gronberg H; Lindberg J
Article: INVESTIGATIONAL NEW DRUGS. 2018;36(4):615-618
Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study
Pappot H; von der Maase H; Ullen A; Agerbaek M
Article: EUROPEAN JOURNAL OF CANCER. 2018;97:33-40
Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab)
Yachnin J; Gilje B; Thon K; Johansson H; Brandberg Y; Panaretakis T; Ullen A
Article: MOLECULAR AND CLINICAL ONCOLOGY. 2018;8(1):141-146
Effect on prostate volume following neoadjuvant treatment with an androgen receptor inhibitor monotherapy versus castration plus an androgen receptor inhibitor in prostate cancer patients intended for curative radiation therapy: A randomised study
Majumder K; Brandberg Y; Johansson H; Castellanos E; Ullen A; Lennernas B; Nilsson S
Article: ONCOIMMUNOLOGY. 2017;6(8):e1338238
Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer
Sarhan D; Leijonhufvud C; Murray S; Witt K; Seitz C; Wallerius M; Xie H; Ullen A; Harmenberg U; Lidbrink E; Rolny C; Andersson J; Lundqvist A
Article: ACTA ONCOLOGICA. 2017;56(1):21-26
Comorbidity as a predictor of overall survival in prostate cancer patients treated with external beam radiotherapy combined with HDR brachytherapy boosts
Hjalm-Eriksson M; Ullen A; Johansson H; Levitt S; Nilsson S; Kalkner K-M
Article: BLOOD. 2016;128(23):2655-2665
Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells
Vardaki I; Sanchez C; Fonseca P; Olsson M; Chioureas D; Rassidakis G; Ullen A; Zhivotovsky B; Bjorkholm M; Panaretakis T
Article: EUROPEAN JOURNAL OF CANCER. 2016;65:43-51
Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study
Majumder K; Nilsson S; Johansson H; Ullen A; Lennernas B; Bergenmar M; Brandberg Y
Article: MEDICINE. 2016;95(31):e4308
Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT
Farnebo J; Wadelius A; Sandstrom P; Nilsson S; Jacobsson H; Blomqvist L; Ullen A
Article: ONCOLOGY LETTERS. 2016;12(2):1293-1300
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
Holmsten K; Dohn LH; Jensen NV; Shah C-H; Jaderling F; Pappot H; Ullen A
Article: MOLECULAR ONCOLOGY. 2016;10(5):719-734
Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma
Viktorsson K; Shah C-H; Juntti T; Haag P; Zielinska-Chomej K; Sierakowiak A; Holmsten K; Tu J; Spira J; Kanter L; Lewensohn R; Ullen A
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2016;5:29877
Energy-requiring uptake of prostasomes and PC3 cell-derived exosomes into non-malignant and malignant cells
Ronquist KG; Sanchez C; Dubois L; Chioureas D; Fonseca P; Larsson A; Ullen A; Yachnin J; Ronquist G; Panaretakis T
Article: INVESTIGATIONAL NEW DRUGS. 2015;33(6):1232-1241
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies
Berglund A; Ullen A; Lisyanskaya A; Orlov S; Hagberg H; Tholander B; Lewensohn R; Nygren P; Spira J; Harmenberg J; Jerling M; Alvfors C; Ringbom M; Nordstrom E; Soderlind K; Gullbo J
Article: ONCOTARGET. 2015;6(25):21740-21754
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel
Kharaziha P; Chioureas D; Rutishauser D; Baltatzis G; Lennartsson L; Fonseca P; Azimi A; Hultenby K; Zubarev R; Ullen A; Yachnin J; Nilsson S; Panaretakis T
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2015;46(1):381-388
Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities
Hjalm-Eriksson M; Lennernas B; Ullen A; Johansson H; Hugosson J; Nilsson S; Brandberg Y
Article: UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2014;32(8):1215-1224
Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6 correlates with prolonged survival in advanced urothelial carcinoma
Shah C-H; Viktorsson K; Kanter L; Sherif A; Asmundsson J; Rosenblatt R; Lewensohn R; Ullen A
Article: BMC CANCER. 2014;14:408
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma
Farnebo J; Gryback P; Harmenberg U; Laurell A; Wersall P; Blomqvist LK; Ullen A; Sandstrom P
Article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(2):76-82
Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
Michaelson MD; Oudard S; Ou Y-C; Sengelov L; Saad F; Houede N; Ostler P; Stenzl A; Daugaard G; Jones R; Laestadius F; Ullen A; Bahl A; Castellano D; Gschwend J; Maurina T; Maneval EC; Wang S-L; Lechuga MJ; Paolini J; Chen I
Article: ANTI-CANCER DRUGS. 2013;24(6):648-652
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient
Shah C-H; Viktorsson K; Sherif A; Kanter L; Gryback P; Lewensohn R; Sandstrom P; Nilsson S; Ullen A
Article: EUROPEAN UROLOGY. 2012;61(6):1229-1238
Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullen A; Nilsson S; Malmstrom P-U
Article: CELL DEATH & DISEASE. 2012;3(1):e262
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells
Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Bjoerklund A-C; Augsten M; Ullen A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
Article: BJU INTERNATIONAL. 2011;108(5):665-672
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma
Benedict A; Figlin RA; Sandstrom P; Harmenberg U; Ullen A; Charbonneau C; Sandin R; Remak E; Hariharan S; Negrier S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2010;37(1):15-20
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro
Ullen A; Farnebo M; Thyrell L; Mahmoudi S; Kharaziha P; Lennartsson L; Grander D; Panaretakis T; Nilsson S
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2009;43(2):98-103
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines
Ullen A; Schwarz S; Lennartsson L; Kalkner K-M; Sandstrom P; Costa F; Lennernas B; Linder S; Nilsson S
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, SUPPLEMENT. 2008;42(218):89-92
Chemotherapy-induced bladder cancer
Nilsson S; Ullen A
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2006;29(6):1517-1524
High dose-rate brachytherapy of prostate cancer utilising Iridium-192 after-loading technique:: Technical and methodological aspects
Edgren M; Ekelund AM; Albertsson P; Lundberg LM; Ullen A; Levitt S; Nilsson S; Lennernas B
Article: ACTA ONCOLOGICA. 2005;44(6):644-650
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid
Ullén A; Lennartsson L; Harmenberg U; Hjelm-Eriksson M; Kalkner KM; Lennernäs B; Nilsson S
Article: ACTA ONCOLOGICA. 2005;44(5):490-495
Prostate cancer cell lines lack amplification:: Overexpression of HER2
Ullén A; Lennartsson L; Harmenberg U; Lennernäs B; Majumder K; Holmberg AR; Nilsson S; Elmberger PG
Article: INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS. 2000;15(1):33-40
A new specific method for measuring S-100B in serum.
Stigbrand T; Nyberg L; Ullén A; Haglid K; Sandström E; Brundell J
Article: IMMUNOLOGY. 1999;97(4):656-664
H-2Dd engagement of Ly49A leads directly to Ly49A phosphorylation and recruitment of SHP1.
Daws MR; Eriksson M; Oberg L; Ullén A; Sentman CL
Article: CANCER RESEARCH. 1999;59(1):48-51
Epitope specificity of the monoclonal anticytokeratin antibody TS1.
Johansson A; Sandström P; Ullén A; Behravan G; Erlandsson A; Levi M; Sundström B; Stigbrand T
Article: CLINICAL CHEMISTRY. 1996;42(10):1702-1708
Analyte and label binding assay read by flow cytometry.
Utgaard JO; Frengen J; Stigbrand T; Ullen A; Schmid R; Lindmo T
Article: CANCER RESEARCH. 1995;55(23 Suppl):5868s-5873s
Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization.
Ullén A; Sandström P; Ahlström KR; Sundström B; Nilsson B; Arlestig L; Stigbrand T
Article: CELL BIOPHYSICS. 1995;27(1):31-45
Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.
Ullén A; Riklund Ahlström K; Makiya R; Stigbrand T
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 1995;183(1):155-165
In vivo and in vitro interactions between idiotypic and antiidiotypic monoclonal antibodies against placental alkaline phosphatase.
Ullén A; Nilsson B; Ahlström KR; Makiya R; Stigbrand T
Article: CANCER RESEARCH. 1995;55(23):S5868-S5873
USE OF ANTICYTOKERATIN MONOCLONAL ANTIIDIOTYPIC ANTIBODIES TO IMPROVE TUMOR/NONTUMOR RATIO IN EXPERIMENTAL RADIOIMMUNOLOCALIZATION
ULLEN A; SANDSTROM P; AHLSTROM KR; SUNDSTROM B; NILSSON B; ARLESTIG L; STIGBRAND T
Visa fler

Alla övriga publikationer

Letter: SCANDINAVIAN JOURNAL OF UROLOGY. 2023;58(1):20
Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019'
Karttunen E; Oldenburg J; Thoresen S; Ullen A
Editorial comment: CANCERS. 2023;15(3):559
Optimal Systemic Treatment of Advanced Bladder Cancer Calls for a Multidisciplinary Approach
Pappot H; Ullen A
Letter: ACTA ONCOLOGICA. 2022;61(12):1515-1516
The optimal neoadjuvant chemotherapy regime for muscle-invasive bladder cancer: still an open question?
Carus A; Holmsten K; Pappot H; Ullen A
Letter: EUROPEAN UROLOGY. 2022;81(4):e92-e93
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjodahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
Sjodahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka N-A; Hoglund M; Ullen A; Liedberg F
Editorial comment: CANCERS. 2020;12(12):E3607-3607
Optimal Systemic Treatment of Advanced Bladder Cancer - A Moving Target
Pappot H; Ullen A
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2019;140:80-87
Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series
Bamias A; Hegele A; Medioni J; Castellano D; Doni L; Passalacqua R; Zagouri F; Tzannis K; Hussain S; Ullen A
Editorial comment: ACTA ONCOLOGICA. 2019;58(7):951-952
Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer
Ullen A
Letter: JAMA ONCOLOGY. 2019;5(7):1060-1062
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer
De Laere B; Rajan P; Gronberg H; Dirix L; Lindberg J; Mayrhofer M; Whitington T; van Dam P-J; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoela L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden G; Rutten A; Del Favero J; Rantalainen M; Sleijfer S; Ullen A; Yachnin J; Van Laere S; De laere L; Develter T; Vantieghem S; Herman S; Coifs G; Lamotte V; Boumans A; Baitar A; Haeck R; Wallays G
Letter: EUROPEAN UROLOGY. 2015;68(4):742-743
A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Prior to Radical Cystectomy: Induction Versus Neoadjuvant Chemotherapy
Liedberg F; Gudjonsson S; Kollberg P; Ullen A
Editorial comment: ACTA ONCOLOGICA. 2011;50:137-140
Management of advanced prostate cancer - new drugs
Ullen A; Shah C-H; Kirkali Z
Review: TUMOR BIOLOGY. 2008;29(5):311-322
Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer
Rosenblatt R; Jonmarker S; Lewensohn R; Egevad L; Sherif A; Kalkner KM; Nilsson S; Valdman A; Ullen A
Letter: ACTA ONCOLOGICA. 2007;46(6):862-863
Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer
Kalkner KM; Ullen A; Wersall P; Cohn-Cedermark G
Published conference paper: CANCER. 2002;94(4 Suppl):1314-1319
The combination of external beam radiotherapy and experimental radioimmunotargeting with a monoclonal anticytokeratin antibody.
Johansson A; Eriksson D; Ullén A; Löfroth P-O; Johansson L; Riklund-Ahlström K; Stigbrand T
Published conference paper: CANCER. 2002;94(4 Suppl):1306-1313
Idiotypic-anti-idiotypic complexes and their in vivo metabolism.
Johansson A; Erlandsson A; Eriksson D; Ullén A; Holm P; Sundström BE; Roux KH; Stigbrand T
Published conference paper: CLINICAL CANCER RESEARCH. 1999;5(10 Suppl):3073s-3078s
Idiotypic-anti-idiotypic antibody interactions in experimental radioimmunotargeting.
Sandström P; Johansson A; Ullén A; Rathsman S; Riklund-Ahlström K; Stigbrand T
Published conference paper: ACTA ONCOLOGICA. 1999;38(3):329-334
Stability and immunoreactivity of the monoclonal anticytokeratin antibody TS1 after different degrees of iodination.
Johansson A; Sandström P; Ullén A; Erlandsson A; Sundström B; Ahlström KR; Johansson L; Hietala SO; Stigbrand T
Published conference paper: CANCER. 1997;80(12 Suppl):2689-2698
Experimental radioimmunotargeting combining nonlabeled, iodine-125-labeled, and anti-idiotypic anticytokeratin monoclonal antibodies: a dosimetric evaluation.
Rossi Norrlund R; Ullén A; Sandström P; Holback D; Johansson L; Stigbrand T; Hietala SO; Riklund Ahlström K
Published conference paper: CANCER. 1997;80(12 Suppl):2681-2688
Dosimetry of fractionated experimental radioimmunotargeting with idiotypic and anti-idiotypic anticytokeratin antibodies.
Rossi Norrlund R; Ullén A; Sandström P; Holback D; Johansson L; Stigbrand T; Hietala SO; Riklund Ahlström K
Published conference paper: CANCER. 1997;80(12 Suppl):2510-2518
Dosimetry of fractionated administration of 125I-labeled antibody at experimental radioimmunotargeting.
Ullén A; Sandström P; Rossi Norrlund R; Rathsman S; Johansson L; Riklund Ahlström K; Hietala SO; Stigbrand T
Published conference paper: CANCER. 1997;80(12 Suppl):2404-2410
Endogenous anti-tumor antibody responses in nude mice.
Stigbrand T; Ullén A; Sandström P; Rathsman S; Rossi Norrlund R; Arlestig L; Riklund Ahlström K; Hietala SO
Published conference paper: ACTA ONCOLOGICA. 1996;35(3):303-307
A putative mechanism for the non-specific uptake of intact radiolabelled monoclonal antibodies in the testes and prostate.
Ahlström KE; Makiya RE; Ullén AP; Damber J; Hietala S; Stigbrand TI
Published conference paper: ACTA ONCOLOGICA. 1996;35(3):281-285
Secondary antibodies as tools to improve tumor to non tumor ratio at radioimmunolocalisation and radioimmunotherapy.
Ullén A; Ahlström KR; Heitala S; Nilsson B; Arlestig L; Stigbrand T
Published conference paper: ACTA ONCOLOGICA. 1996;35(3):259-265
Twenty years with monoclonal antibodies: State of the art--Where do we go?
Stigbrand T; Ullén A; Sandstrom P; Mirzaie-Joniani H; Sundström B; Nillson B; Arlestig L; Norrlund RR; Ahlström KR; Hietala S
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI